Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Flagged first, then by citations

Show all 9 references

Sorted by citations

Items 801–900 of 1,009

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine
Baldelli, E., Haura, E. B., Crinò, L., Cress, W. D., Ludovini, V., Schabath, M. B., Liotta, L. A., Petricoin, E. F., & Pierobon, M. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400056 · Cited by 34
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Zhang, S., Li, L., Wang, T., Bian, L., Hu, H., Xu, C., Liu, B., Liu, Y., Cristofanilli, M., & Jiang, Z. (2016) · BMC Cancer · doi:10.1186/s12885-016-2578-5 · Cited by 34
Quantitative diagnosis of HER 2 protein expressing breast cancer by single‐particle quantum dot imaging
Miyashita, M., Gonda, K., Tada, H., Watanabe, M., Kitamura, N., Kamei, T., Sasano, H., Ishida, T., & Ohuchi, N. (2016) · Cancer Medicine · doi:10.1002/cam4.898 · Cited by 34
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
Liang, Y., Chen, J., Yu, Q., Ji, T., Zhang, B., Xu, J., Dai, Y., Xie, Y., Lin, H. M., Liang, X., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1228 · Cited by 34
Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity
Udagawa, C., Nakamura, H. K., Ohnishi, H., Tamura, K., Shimoi, T., Yoshida, M., Yoshida, T., Totoki, Y., Shibata, T., & Zembutsu, H. (2017) · Cancer Science · doi:10.1111/cas.13471 · Cited by 34
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Ding, Y., Gong, C., Huang, D., Chen, R., Sui, P., Lin, K., Liang, G., Yuan, L., Xiang, H., Chen, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06651-x · Cited by 35
Targeting HER 2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
Harris, F. R., Zhang, P., Yang, L., Hou, X., Leventakos, K., Weroha, S. J., Vasmatzis, G., & Kovtun, I. V. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12414 · Cited by 34
Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
Li, L., Deng, L., Meng, X., Gu, C., Li, M., Li, K., Zhang, X., Meng, Y. F., Xu, W., Zhao, L., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100916 · Cited by 34
Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer
O'Sullivan, C. C., Ballman, K. V., McCall, L. M., Kommalapati, A., Zemla, T., Weiss, A. C., Mitchell, M. P., Blinder, V. S., Tung, N., Irvin, W. J., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0753 · Cited by 34
Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy
Behravan, N., Zahedipour, F., Jaafari, M. R., Johnston, T. P., & Sahebkar, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120294 · Cited by 34
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival
Nishimura, R., Okumura, Y., & Arima, N. (2007) · Breast Cancer · doi:10.1007/s12282-007-0014-z · Cited by 34
New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up
Jensen, K. C., Turbin, D. A., Leung, S. C. Y., Miller, M. A., JOHNSON, K., Norris, B. D., Hastie, T. J., McKinney, S. E., Nielsen, T. O., Huntsman, D. D., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9887-y · Cited by 34
Fully Automated Fluorescent in situ Hybridization (FISH) Staining and Digital Analysis of HER2 in Breast Cancer: A Validation Study
van der Logt, E. M. J., Kuperus, D. A. J., van Setten, J. W., van den Heuvel, M. C., Boers, J. E., Schuuring, E. M. D., & Kibbelaar, R. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123201 · Cited by 34
A positive role for PEA3 in HER2-mediated breast tumour progression
Myers, E. A., Hill, A. D. K., Kelly, G., McDermott, E. W. M., O’Higgins, N. J., & Young, L. S. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603427 · Cited by 34
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study
Martín, M., Sánchez‐Rovira, P., Muñoz-Mateu, M., Baena-Cañada, J. M., Mel, J. R., Vila, M. M., Ramos, M., Martínez, E., García-Sáenz, J. Á., Casado, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr024 · Cited by 34
The molecular mechanism and clinical significance of LDHA in HER2-mediated progression of gastric cancer.
Zhu, W., Ma, L., Qian, J., Xu, J., Xu, T., Pang, L., Zhou, H., Shu, Y., & Zhou, J. (2018) · Europe PMC (PubMed Central) · Cited by 34
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
Schmidt, M., Lewark, B., Nikolai, K., Glawatz, C., Erik, S., Tanner, B., Pilch, H., Weikel, W., KÖLBL, H., & Lehr, H. (2005) · Breast Cancer Research · doi:10.1186/bcr991 · Cited by 34
Antisense clusterin oligodeoxynucleotides increase the response of HER‐2 gene amplified breast cancer cells to Trastuzumab
Biroccio, A., D’Angelo, C., Jansen, B., Gleave, M. E., & Zupi, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20295 · Cited by 34
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
Lu, N. T., Raizer, J. J., Gabor, E. P., Liu, N. M., Vu, J. Q., Slamon, D. J., & Barstis, J. L. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0084-y · Cited by 33
Self-citation
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling
Wang, X., Li, G., Koul, S., Ohki, R., Maurer, M., Borczuk, A., & Halmos, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3674 · Cited by 34
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
Cheng, H., Ballman, K. V., Vassilakopoulou, M., Dueck, A. C., Reinholz, M. M., Tenner, K., Gralow, J. R., Hudis, C. A., Davidson, N. E., Fountzilas, G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.442 · Cited by 33
Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors
Zhou, H. Y., Hittelman, W. N., Yagita∥, H., Cheung, L. H., Martin, S. S., Winkles, J. A., & Rosenblum, M. G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0187 · Cited by 33
Screening protein isoforms predictive for cancer using immunoaffinity capture and fast LC‐MS in PRM mode
Lesur, A., Ancheva, L., Kim, Y. J., Berchem, G., van Oostrum, J., & Domon, B. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400158 · Cited by 33
Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
Mattos‐Arruda, L. D., & Cortés, J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0187 · Cited by 34
Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma
Li, L., Luo, C., Song, Z., Reyes‐Vargas, E., Clayton, F., Huang, J., Jensen, P. E., & Chen, X. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.11.001 · Cited by 33
An Overview of Cancer Immunotherapeutic Strategies
Wahid, B., Ali, A., Rafique, S., Waqar, M., Wasim, M., Wahid, K., & Idrees, M. (2018) · Immunotherapy · doi:10.2217/imt-2018-0002 · Cited by 33
The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications
Furrer, D., Paquet, C., Jacob, S., & Diorio, C. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.78271 · Cited by 33
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1620 · Cited by 32
A Validation Study of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Digital Imaging Analysis and its Correlation with Human Epidermal Growth Factor Receptor 2 Fluorescence In situ Hybridization Results in Breast Carcinoma
Hartage, R., Li, A. C., Hammond, S., & Parwani, A. V. (2020) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_52_19 · Cited by 34
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Cancer of the Breast
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 37
The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies
Sweet, S. M. M., Chain, D. C., Yu, W., Martin, P., Rebelatto, M. C., Chambers, A. G., Cecchi, F., & Kim, Y. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-16358-1 · Cited by 30
HER2 expression as a potential marker for response to therapy targeted to the EGFR
Emlet, D. R., Schwartz, R. S., Brown, K. A., Pollice, A. A., Smith, C. A., & Shackney, S. E. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603078 · Cited by 33
CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/ neu –Expressing Cancers
Datta, J., Xu, S., Rosemblit, C., Smith, J. B., Cintolo, J. A., Powell, D. J., & Czerniecki, B. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0208 · Cited by 33
The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer
Diaz, L. K., Gupta, R., Kidwai, N., Sneige, N., & Wiley, E. L. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540405200408 · Cited by 33
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Maeng, H. M., Moore, B. N., Bagheri, H., Steinberg, S. M., Inglefield, J. R., Dunham, K., Wei, W., Morris, J. C., Terabe, M., England, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.789078 · Cited by 35
Treatment strategy for HER2-positive breast cancer
Mukai, H. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0107-0 · Cited by 33
Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging
Gonda, K., Miyashita, M., Higuchi, H., Tada, H., Watanabe, T. M., Watanabe, M., Ishida, T., & Ohuchi, N. (2015) · Scientific Reports · doi:10.1038/srep14322 · Cited by 32
Rationale for immunological approaches to breast cancer therapy
Monnot, G., & Romero, P. J. (2017) · The Breast · doi:10.1016/j.breast.2017.06.009 · Cited by 34
The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines
Abdel‐Latif, G. A., Al-Abd, A. M., Tadros, M. G., Al-Abbasi, F. A., Khalifa, A. E., & Abdel‐Naim, A. B. (2015) · Scientific Reports · doi:10.1038/srep12054 · Cited by 32
HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma
Purdie, C. A., Jordan, L. B., McCullough, J. B., Edwards, S. L., Cunningham, J., Walsh, M., Grant, A., Pratt, N., & Thompson, A. M. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03533.x · Cited by 32
Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts
Whisenant, J. G., Sorace, A. G., McIntyre, J. O., Kang, H., Sanchez, V. M., Loveless, M. E., & Yankeelov, T. E. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.09.011 · Cited by 32
Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer
Downey, L., Livingston, R. B., Koehler, M. T., Arbushites, M. C., Williams, L., Santiago, A., Guzman, R., Villalobos, I. E., Leo, A. D., & Press, M. F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1643 · Cited by 31
Self-citation
Cardiovascular Complications of Breast Cancer Therapy in Older Adults
Shenoy, C., Klem, I., Crowley, A. L., Patel, M. R., Winchester, M. A., Owusu, C., & Kimmick, G. G. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0348 · Cited by 32
Integrating text mining, data mining, and network analysis for identifying genetic breast cancer trends
Jurca, G., Addam, O., Aksaç, A., Gao, S. B., Özyer, T., Demetrick, D. J., & Alhajj, R. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2023-5 · Cited by 33
PHARMACOGENETICS APPROACH TO THERAPEUTICS
Koo, S. H., & Lee, E. J. D. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04402.x · Cited by 32
HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production
Simeone, A., Broemeling, L. D., Rosenblum, J., & Tari, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206786 · Cited by 32
Correlation of immunophenotype with progression‐free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate
Chirieac, L. R., Trent, J. C., Steinert, D. M., Choi, H., Yang, Y., Zhang, J., PATEL, S. R., Benjamin, R. S., & Raymond, A. K. (2006) · Cancer · doi:10.1002/cncr.22226 · Cited by 32
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Dey, N., Sun, Y., Carlson, J. H., Wu, H., Lin, X., Leyland-Jones, B. R., & De, P. K. (2016) · PubMed · Cited by 31
Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes
Amin, M., Pourshohod, A., Kheirollah, A., Afrakhteh, M., Gholami-Borujeni, F., Zeinali, M., & Jamalan, M. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.07.017 · Cited by 31
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
Xu, B., Hu, X., Feng, J., Geng, C., Jin, F., Li, H., Li, M., Li, Q., Liao, N., Liu, D., et al. (2020) · Cancer · doi:10.1002/cncr.32832 · Cited by 32
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Leo, A. D. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8951 · Cited by 31
Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
Yang, L., Li, Y., & Zhang, Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.187 · Cited by 31
Copper-64 trastuzumab PET imaging: a reproducibility study
Carrasquillo, J. A., Morris, P. G., Humm, J. L., Smith-Jones, P. M., Beylergil, V., Akhurst, T., O’Donoghue, J. A., Ruan, S., Modi, S., Hudis, C. A., et al. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.16.02867-3 · Cited by 31
Over-treatment in metastatic breast cancer
Senkus, E., & Łacko, A. (2016) · The Breast · doi:10.1016/j.breast.2016.06.024 · Cited by 32
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
Venturini, M., Bighin, C., Monfardini, S., Cappuzzo, F., Olmeo, N. A., Durando, A., Puglisi, F., Nicoletto, O., Lambiase, A., & Mastro, L. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9030-x · Cited by 31
p185 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease
Reich, O., Liegl, B., Tamussino, K. F., & Regauer, S. (2004) · Modern Pathology · doi:10.1038/modpathol.3800243 · Cited by 31
Gemtuzumab Ozogamicin: One Size Does Not Fit All—The Case for Personalized Therapy
Ravandi, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2693 · Cited by 31
An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer
Ruiz, M., Salvador, J., Bayo, J. L., Lomas, M., Moreno, A., Valero, M., Bernabé, R., Vicente, D., Jiménez, J., & López-Ladrón, A. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0709-7 · Cited by 30
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
Bates, M. P., Sperinde, J., Köstler, W. J., Ali, S. M., Leitzel, K., Fuchs, E., Paquet, A. C., Lie, Y., Sherwood, T., Horvat, R., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq706 · Cited by 30
Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies
Blank, P. R., Schwenkglenks, M. M., Moch, H., & Szucs, T. D. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0862-7 · Cited by 30
Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)
Kato, N., Itoh, H., Serizawa, A., Hatanaka, Y., Umemura, S., & OSAMURA, R. Y. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02553.x · Cited by 30
Exosomal-mediated transfer of OIP5-AS1 enhanced cell chemoresistance to trastuzumab in breast cancer via up-regulating HMGB3 by sponging miR-381-3p
Yu, Q., Li, Y., Peng, S., Li, J., & Qin, X. (2021) · Open Medicine · doi:10.1515/med-2021-0249 · Cited by 30
YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers
Sardo, F. L., Canu, V., Maugeri‐Saccà, M., Strano, S., & Blandino, G. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188756 · Cited by 30
Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors
Nevins, S., McLoughlin, C. D., Oliveros, A., Stein, J. B., Rashid, M. A., Hou, Y., Jang, M., & Lee, K. (2023) · Small · doi:10.1002/smll.202300744 · Cited by 31
Targeting Human Epidermal Growth Factor Receptor Signaling with the Neuregulin's Heparin-binding Domain
Ma, Z., Li, Q., An, H., Pankonin, M. S., Wang, J., & Loeb, J. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032714 · Cited by 31
HER2 and hormone receptor-positive breast cancer—blocking the right target
Cortés, J., Saura, C., Bellet, M., Muñoz‐Couselo, E., Ramírez-Merino, N., Calvo, V., Pérez-García, J. M., & Vidal, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.185 · Cited by 30
The Role of ErbB Inhibitors in Trastuzumab Resistance
Miller, K. D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-16 · Cited by 30
A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
Bussolati, G., Montemurro, F., Righi, L., Donadio, M., Aglietta, M., & Sapino, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602507 · Cited by 30
Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group
Borghaei, H., Alpaugh, R. K., Bernardo, P., de Palazzo, I. G., Dutcher, J. P., Venkatraj, U., Wood, W. C., Goldstein, L. J., & Weiner, L. M. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31803bb421 · Cited by 31
Expression of G protein‐coupled receptor kinase 4 is associated with breast cancer tumourigenesis
Matsubayashi, J., Takanashi, M., Oikawa, K., Fujita, K., Tanaka, M., Xu, M., Blasi, A. D., Bouvier, M., Kinoshita, M., Kuroda, M., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2414 · Cited by 30
Trastuzumab and Antiestrogen Therapy
Ocaña, A., Cruz, J. J., & Pandiella, A. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000190274.00570.0a · Cited by 30
Pharmacogenomics and the Drug Discovery Pipeline
Penny, M. A., & McHale, D. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505010-00005 · Cited by 30
Pharmacogenomics
Ross, J. S., Schenkein, D. P., Kashala, O., Linette, G. P., Stec, J. J., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2004) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000131825.77317.ee · Cited by 30
Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
Koo, T., & Kim, I. A. (2016) · Radiation Oncology Journal · doi:10.3857/roj.2016.34.1.1 · Cited by 28
Mucins in neoplasms of pancreas, ampulla of Vater and biliary system
Moschovis, D., Bamias, G., & Delladetsima, I. K. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i10.725 · Cited by 29
Ado-Trastuzumab Emtansine (T-DM1) in HER2+ Advanced Breast Cancer Patients: does Pretreatment with Pertuzumab Matter?
Fabi, A., Giannarelli, D., Moscetti, L. I., Santini, D., Zambelli, A., Laurentiis, M. D., Caruso, M., Generali, D., Valle, E., Leonardi, V. B., et al. (2017) · Future Oncology · doi:10.2217/fon-2017-0336 · Cited by 29
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer
Syed, A., Woodall, R. T., Whisenant, J. G., Yankeelov, T. E., & Sorace, A. G. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.008 · Cited by 31
Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
Wu, Y., Sarkissyan, M., Ogah, O., Kim, J., & Vadgama, J. V. (2020) · Cancers · doi:10.3390/cancers12071918 · Cited by 29
Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 30
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
Ferreira, R. B., Law, M. E., Jahn, S. C., Davis, B. J., Heldermon, C. D., Reinhard, M. K., Castellano, R. K., & Law, B. K. (2015) · Oncotarget · doi:10.18632/oncotarget.3398 · Cited by 27
Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/ neu expressing tumors
Helguera, G. F., Rodríguez, J. A., & Penichet, M. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0488 · Cited by 29
High-throughput measurements of the optical redox ratio using a commercial microplate reader
Cannon, T. M., Shah, A. T., Walsh, A. J., & Skala, M. C. (2015) · Journal of Biomedical Optics · doi:10.1117/1.jbo.20.1.010503 · Cited by 29
Somatic pharmacogenomics in cancer
Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
Şahin, Ö., Wang, Q., Brady, S. W., Ellis, K., Wang, H., Chang, C., Zhang, Q., Priya, P., Zhu, R., Wong, S. T. C., et al. (2014) · Cell Research · doi:10.1038/cr.2014.37 · Cited by 29
Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice
Xie, Y., Wu, J., Xu, A., Ahmeqd, S., Sami, A., Chibbar, R., Freywald, A., Zheng, C., & Xiang, J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.078 · Cited by 29
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies
Cunliffe, T. G., Bates, E. A., & Parker, A. L. (2020) · Cancers · doi:10.3390/cancers12113327 · Cited by 29
HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab
O’Malley, F. P., Thomson, T., Julian, J. A., Have, C. L., Cosby, R., Gelmon, K. A., Andrulis, I. L., & Whelan, T. J. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-61-htiaps · Cited by 29
Controversies in the Assessment of HER-2
Leong, T. Y.-M., & Leong, A. S. ‐. (2006) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000213043.16200.92 · Cited by 29
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant
Kirkegaard, T., Hansen, S. K., Larsen, S. L., Reiter, B. E., Sørensen, B. S., & Lykkesfeldt, A. E. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.014 · Cited by 28
Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment
Andreasen, S., Grauslund, M., & Heegaard, S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13310 · Cited by 28
Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression
Tian, Z., Tang, J., Yang, Q., Li, X., Zhu, J., & Wu, G. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109414 · Cited by 27
The Evolving Landscape of HER2-Directed Breast Cancer Therapy
Marti, J. L. G., Hyder, T., Nasrazadani, A., & Brufsky, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00780-6 · Cited by 28
Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment
Saini, S., Gulati, N., Awasthi, R., Arora, V., Singh, S. K., Kumar, S., Gupta, G., Dua, K., Pahwa, R., & Dureja, H. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230731094258 · Cited by 29
High‐level ERBB2 gene amplification is associated with a particularly short time‐to‐metastasis, but results in a high rate of complete response once trastuzumab‐based therapy is offered in the metastatic setting
Fuchs, E., Köstler, W. J., Horvat, R., Hudelist, G., Kubista, E., Attems, J., Zielinski, C. C., & Singer, C. F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28660 · Cited by 28
Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression
Stewart, J. E., James, J. A., McCluggage, G., McQuaid, S., Arthur, K., Boyle, D., Mullan, P. B., McArt, D. G., Yan, B., Irwin, G. W., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.114 · Cited by 28
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Gilbertson, R. J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-508 · Cited by 28

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks